Detalhe da pesquisa
1.
Research autopsy programmes in oncology: shared experience from 14 centres across the world.
J Pathol
; 263(2): 150-165, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38551513
2.
BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme.
Histopathology
; 83(1): 91-103, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36999648
3.
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.
Genet Med
; 24(1): 119-129, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34906479
4.
Novel germline mutations for active surveillance and imaging strategies in prostate cancer.
Curr Opin Urol
; 32(5): 456-461, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35855555
5.
Whole-genome characterization of chemoresistant ovarian cancer.
Nature
; 521(7553): 489-94, 2015 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26017449
6.
Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells.
BJU Int
; 121(6): 971-978, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28977728
7.
Correction: The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE".
PLoS Med
; 14(4): e1002302, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28430777
8.
Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab.
Genet Med
; 19(1): 30-35, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27171545
9.
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.
Genet Med
; 24(10): 2208, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36205748
10.
Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.
J Med Genet
; 53(1): 34-42, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26534844
11.
The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE".
PLoS Med
; 13(12): e1002204, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28027312
12.
Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.
Nature
; 527(7578): 398, 2015 Nov 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26503049
13.
Altered significance of D'Amico risk classification in patients with prostate cancer linked to a familial breast cancer (kConFab) cohort.
BJU Int
; 116(2): 207-12, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24784491
14.
Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles.
PLoS Genet
; 8(9): e1002894, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23028338
15.
Improving mutation notification when new genetic information is identified in research: a trial of two strategies in familial breast cancer.
Genet Med
; 15(3): 187-94, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22975758
16.
Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer.
Nat Genet
; 55(3): 437-450, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36849657
17.
Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.
Eur J Cancer
; 185: 105-118, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36972661
18.
High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
BJU Int
; 110(11 Pt C): E1181-6, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23035815
19.
Novel Germline Mutations in a Cohort of Men with Familial Prostate Cancer.
Cancers (Basel)
; 14(15)2022 Jul 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35892882
20.
Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status.
Cancers (Basel)
; 14(16)2022 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36010941